Mizuho raised the firm’s price target on Pediatrix Medical (MD) to $15 from $13 and keeps a Neutral rating on the shares. The company, which provides neonatal and pediatric services to hospitals, is the largest provider of outsourced neonatal intensive care in the U.S. but the firm views EPS visibility as low given the low birth rates in the U.S. coupled with execution challenges, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Medical price target raised to $18 from $14 at Jefferies
- Pediatrix Medical price target raised to $15 from $10 at Leerink
- Pediatrix Medical price target raised to $16 from $13 at Truist
- Pediatrix Medical price target raised to $15 from $9 at Deutsche Bank
- Pediatrix Medical price target raised to $15 from $13 at Mizuho